0 251

Cited 155 times in

The Effect of Topical Bevacizumab on Corneal Neovascularization

Authors
 Sang Woo Kim  ;  Byung Jin Ha  ;  Eung Kweon Kim  ;  Hungwon Tchah  ;  Tae-im Kim 
Citation
 OPHTHALMOLOGY, Vol.115(6) : 33-38, 2008 
Journal Title
 OPHTHALMOLOGY 
ISSN
 0161-6420 
Issue Date
2008
MeSH
Administration, Topical ; Adolescent ; Adult ; Angiogenesis Inhibitors/administration & dosage* ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal/administration & dosage* ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Corneal Neovascularization/drug therapy* ; Corneal Neovascularization/physiopathology ; Epithelium, Corneal/drug effects ; Epithelium, Corneal/pathology ; Female ; Humans ; Intraocular Pressure/drug effects ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Tonometry, Ocular ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/drug effects
Keywords
Administration, Topical ; Adolescent ; Adult ; Angiogenesis Inhibitors/administration & dosage* ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal/administration & dosage* ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Corneal Neovascularization/drug therapy* ; Corneal Neovascularization/physiopathology ; Epithelium, Corneal/drug effects ; Epithelium, Corneal/pathology ; Female ; Humans ; Intraocular Pressure/drug effects ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Tonometry, Ocular ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/drug effects
Abstract
PURPOSE: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. DESIGN: Prospective, nonrandomized, masked observational case series. PARTICIPANTS: Ten eyes of 7 patients with corneal NV. METHODS: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. MAIN OUTCOME MEASURES: Corneal NV and changes in ophthalmic evaluations. RESULTS: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. CONCLUSIONS: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.
Full Text
http://www.sciencedirect.com/science/article/pii/S0161642008001760
DOI
10.1016/j.ophtha.2008.02.013
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sang Woo(김상우)
Kim, Eung Kweon(김응권) ORCID logo https://orcid.org/0000-0002-1453-8042
Kim, Tae Im(김태임) ORCID logo https://orcid.org/0000-0001-6414-3842
Ha, Byoung Jin(하병진)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/108189
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse